Analyst Ratings For Cara Therapeutics (NASDAQ:CARA)
Today, Cara Therapeutics (NASDAQ:CARA) stock received an upgrade by Janney Montgomery Scott from Neutral to Buy with a price target of $21.00.
Some recent analyst ratings include
- 2/12/2018-Janney Montgomery Scott Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 1/19/2018-Seaport Global Securities initiated coverage with a Buy rating.
- 1/3/2018-Stifel Nicolaus Reiterated Rating of Buy.
- 11/7/2017-BMO Capital Markets Reiterated Rating of Market Perform.
Recent Insider Trading Activity For Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics (NASDAQ:CARA) has insider ownership of 7.50% and institutional ownership of 58.98%.
- On 1/24/2018 Derek T Chalmers, CEO, sold 12,500 with an average share price of $15.00 per share and the total transaction amounting to $187,500.00.
- On 1/24/2018 Frederique Ph.D. Menzaghi, SVP, sold 15,000 with an average share price of $15.00 per share and the total transaction amounting to $225,000.00.
- On 11/1/2017 Derek T Chalmers, CEO, sold 16,000 with an average share price of $12.66 per share and the total transaction amounting to $202,560.00.
- On 7/14/2017 Derek T Chalmers, CEO, sold 25,000 with an average share price of $15.05 per share and the total transaction amounting to $376,250.00.
- On 7/14/2017 Frederique Ph.D. Menzaghi, VP, sold 3,000 with an average share price of $15.00 per share and the total transaction amounting to $45,000.00.
- On 6/29/2017 Dean Slagel, Director, sold 250,000 with an average share price of $25.87 per share and the total transaction amounting to $6,467,500.00.
- On 3/31/2017 Ventures Vi Lp Rho, Major Shareholder, bought 500,000 with an average share price of $18.19 per share and the total transaction amounting to $9,095,000.00.
Recent Trading Activity for Cara Therapeutics (NASDAQ:CARA)
Shares of Cara Therapeutics closed the previous trading session at 12.80 up +0.50 4.07% with 12.610099792480469 shares trading hands.
